Xuming Zhusan Decoction Attenuates Post‐Stroke via Modulating TLR4/MYD88/NF‐κB Pathway in Mice
Brief intro:
- Author: Xi Liu, Cheng Wang, Ling Han, Yi'an Xiao, Hanchang Yu, Zhongxu Hu, Xiyun Fei, Min Peng, Jilin Zhou, Zhijun Zhong
- Journal: Food Science & Nutrition
- Doi: https://www.doi.org/10.1002/fsn3.71734
- Publication Date: 2026/4/16
Abstract
Ischemic stroke induces neuroinflammation that exacerbates neuronal damage. The Chinese Medicine Xuming Zhusan (XMZS) has shown promising efficacy in stroke treatment, but its mechanisms are unclear. This study aimed to explore the effect of XMZS on microglial‐mediated neuroinflammation and explore its molecular targets. In vivo experiments were conducted using a mouse model of cerebral ischemia–reperfusion injury induced by middle cerebral artery occlusion (MCAO), and in vitro studies were performed on primary microglia and cortical neurons with Oxygen–Glucose Deprivation/Reoxygenation (OGD/R) models. Behavioral assessments, histological analyses, Western blotting, co‐immunoprecipitation, confocal microscopy, and enzyme‐linked immunosorbent assay (ELISA) were employed to evaluate the neuroprotective effects of XMZS and its regulatory role in the TLR4/MYD88/NF‐κB pathway. Results showed that high‐dose (63 g/kg) XMZS improved neurological and cognitive functions, reduced infarct volume and brain edema in MCAO mice. Mechanistically, XMZS suppressed microglial activation, decreased the levels of pro‐inflammatory cytokines (IL‐1β, IL‐6, TNF‐α), and downregulated the expression of TLR4, MYD88, and phosphorylated p65 in the TLR4/MYD88/NF‐κB pathway. Additionally, cinditioned medium from XMZS‐treated microglia enhanced the viability of primary neurons. In conclusion, XMZS exerts neuroprotective effects against cerebral ischemia–reperfusion injury by modulating the TLR4/MYD88/NF‐κB pathway, thereby attenuating microglia‐mediated neuroinflammation.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
